Frontier Medicines, located in South San Francisco, CA and Boston, MA, is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. We are deploying our technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines against the most important drivers of disease. Our lead program targets both the activated and inactive forms of KRAS G12C, a validated driver in a number of cancers that until recently has been undruggable. Our pipeline embodies our vision of bolding advancing science to defeat disease, starting with cancer.
Location: United States, California, San Francisco
Employees: 51-200
Total raised: $235.5M
Founded date: 2018
Founders name: Chris Varma
Founders Related Locations: United States, California, San Francisco
Investors 6
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | DCVC | dcvc.com/ |
| - | RA Capital... | racap.com |
| - | Droia Onco... | droiaventu... |
| - | Berkeley C... | berkeleyca... |
| - | MPM BioImp... | mpmbioimpa... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 27.02.2024 | Series C | $80M | - |
| 20.07.2021 | Series B | $88.5M | - |
| 25.06.2019 | Series A | $67M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Chris | Varma | Co-Founder... | linkedin.c... | - | - |
Mentions in press and media 23
| Date | Title | Description |
| 25.06.2024 | Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension | Gerardo Ubaghs brings high-profile global biopharma strategic and capital markets experience as newly appointed Chief Financial Officer (CFO)Company adds $20 million to close oversubscribed Series C totaling $100 millionFinancing supports d... |
| 06.03.2024 | Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024 | - |
| 27.02.2024 | Frontier Medicines: Oversubscribed $80 Million Funding Round Raised To Support Progress of Clinical-Stage Pipeline | Frontier Medicines – a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets – announced the closing of an oversubscribed $80 million Series C f... |
| 26.02.2024 | Retail investors have been clamoring to invest in AI. With Fundrise, there’s now a path into private AI juggernaut Anthropic. | The old saying goes something like this: If you can’t get in the front door, go through the back, and if you can’t get in through the back door, find a window. Now retail investors have found the window to get in on hot AI startup Anthropic... |
| 25.02.2024 | Frontier Medicines Receives $80M in Series C Financing | Frontier Medicines Corporation, a Boston, MA- and San Francisco, CA-based precision medicine company developing therapies against otherwise undruggable disease-causing targets, received $80M in Series C funding. The round, which brought the... |
| 23.02.2024 | Frontier Medicines Secures $80 Million for Clinical-Stage Pipeline | Frontier Medicines, a precision medicine company, has successfully closed an oversubscribed $80 million Series C financing round. This funding will propel the progress of their clinical-stage pipeline, with a focus on the first-in-class dir... |
| 23.02.2024 | Frontier Medicines Inks $80M Series C | BOSTON, MA, Frontier Medicines today announced the close of an oversubscribed $80 million Series C financing. >> Click here for more funding data on Frontier Medicines >> To export Frontier Medicines funding data to PDF and ... |
| 22.02.2024 | Galapagos kondigt 2023 jaarresultaten en vooruitzichten 2024 aan | Financiële kerngetallen voor het hele jaar 2023: Netto groepsomzet van €783,5 miljoen in 2023, inclusief €112,3 miljoen nettoverkopen voor Jyseleca® Geldmiddelen en kortlopende financiële investeringen van €3,7 miljard per 31 december 2023 ... |
| 22.02.2024 | Galapagos announces full year 2023 results and outlook for 2024 | Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operational cash burni of €414.8 million, within... |
| 22.02.2024 | Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline | - |
Show more